Skip to main content
Journals

Efficacy and Safety of IncobotulinumtoxinA for the Simultaneous Treatment of Upper Facial Lines: A GRADE Assessed Systematic Review and Meta-analysis

Aesthetic Surgery Journal Open Forum
Aesthetic Surgery Journal Open Forum

Authors: Muhammad Tayyab Azam, MBBS , Muhammad Hussain Azam, MBBS , Muhammad Hassan Azam, MBBS , Shahzad Ashraf, MBBS , Muhammad Arif Khan, MBBS , Hasibullah Aminpoor, MD

Abstract: Upper facial lines (UFLs), including glabellar frown lines (GFLs), horizontal forehead lines (HFLs), and lateral canthal lines (LCLs) are prevalent aesthetic concerns addressed with botulinum neurotoxin type A (BoNT-A). IncobotulinumtoxinA, a highly purified BoNT-A formulation, is utilized for simultaneous UFLs treatment; yet, comprehensive synthesized evidence is limited. This study aimed to systematically evaluate the efficacy and safety of IncobotulinumtoxinA compared with placebo for the simultaneous treatment of UFLs in adults, following PRISMA 2020 guidelines. Comprehensive searches of PubMed, Embase, Cochrane CENTRAL, ICTRP, and ClinicalTrials.gov were performed to identify randomized controlled trials (RCTs) evaluating IncobotulinumtoxinA for combined UFLs treatment. The primary outcome was ≥1-grade improvement on Day 30. Secondary outcomes included ≥2-grade improvement and Global Aesthetic Improvement Scale (GAIS) scores. Safety outcomes included adverse events (AEs), treatment-emergent adverse events (TEAEs), and headaches. Three RCTs (n = 704) were included. Pooled analysis using random-effects model demonstrated a significant ≥1-grade improvement at Day 30 in IncobotulinumtoxinA compared with placebo across all regions: GFLs (RR 21.49, 95% CI: 9.89-46.73), HFLs (RR 19.17, 95% CI: 9.23-39.80), and LCLs (RR 11.68, 95% CI: 7.49-18.20), all P < .00001. A ≥ 2-grade improvement similarly favored treatment across all areas (RRs 76.26-115.04; all P < .00001). Investigator-assessed GAIS scores also improved significantly (MD 2.29, 95% CI: 2.11-2.46, P < .00001). Serious AEs were lower with IncobotulinumtoxinA (RR 0.14, P = .03). There was no significant difference in TEAEs and headaches from placebo. IncobotulinumtoxinA demonstrates statistically significant efficacy and a comparable safety profile vs placebo for simultaneous UFLs treatment. These findings support its use in aesthetic practice, warranting further long-term investigation.

JOURNAL ARTICLE

Related Articles

Melasma is a chronic, relapsing hyperpigmentation disorder that is difficult to treat, particularly in Fitzpatrick skin types III-V, where energy-based devices frequently induce postinflammatory hyperpigmentation (PIH). Radiofrequency microneedling (RFMN) has emerged as a promising alternative because it targets dermal pathology while minimizing epidermal injury.
Hyaluronidase is often described as “dissolving” dermal filler, but this term oversimplifies how the enzyme actually interacts with long-standing filler within living tissue. This article explains why hyaluronidase more accurately modifies a complex filler–tissue system rather than completely eliminating filler, and why clearer terminology improves patient understanding, clinical decision-making, and ethical practice in aesthetic medicine.
Conventional botulinum toxin type A (BoNT/A) products include non-therapeutic accessory proteins vary in composition and manufacturing processes, which may contribute to differences in purity and biochemical characteristics. YY001 (Retoxin®) is a novel recombinant BoNT/A manufactured via E. coli expression to reduce impurities, improve purity, and minimize immunogenic risk.
Energy-based devices are widely used for facial rejuvenation; as a result, an increasing proportion of patients presenting for facelift or necklift surgery have a history of prior treatment with ultrasound- or radiofrequency-based technologies. While the efficacy and safety of these devices are well established, their cumulative effects on facial soft tissues critical to deep-layer facelift surgery remain under-recognized.